← All organizations
Highest phase reached
Phase 3
First clinical trial
Jul 1, 2007First marketed drug
Aug 10, 2018First NDA
Aug 10, 2018Last known activity
Dec 31, 2025
Timeline
2000s
- Jun 2, 2002
Alnylam Pharmaceuticals— Founded
2020s
- Jun 13, 2022
vutrisiran— Marketing Organization
Drugs by trial phase (40 distinct, 73 trials)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (14 own, 0 via acquisition)
Phase 1 (18 own, 0 via acquisition)
Indications
Studied for
- alpha 1-Antitrypsin Deficiency
- Amyloid Neuropathies
- Amyloid Neuropathies, Familial
- Amyloidosis
- Amyloidosis, Familial
- Atypical Hemolytic Uremic Syndrome
- Azotemia
- Cardiomyopathies
- Communicable Diseases
- Coproporphyria, Hereditary
- Disease Progression
- Fatty Liver
- Glomerulonephritis
- Glomerulonephritis, IGA
- Hemoglobinuria
- Hemoglobinuria, Paroxysmal
- Hemolysis
- Hemolytic-Uremic Syndrome
- Hemophilia A
- Hemophilia B
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Hypercholesterolemia
- Hyperoxaluria, Primary
- Hypertension
- Infections
- Kidney Diseases
- Liver Diseases
- Neoplasms
- Non-alcoholic Fatty Liver Disease
- Polyneuropathies
- Porphyria, Acute Intermittent
- Porphyria, Erythropoietic
- Porphyrias
- Porphyrias, Hepatic
- Porphyria, Variegate
- Respiratory Syncytial Virus Infections
- Syndrome
- Virus Diseases
Marketed drugs (4)
Recent trials (50)
- NCT04056481Study directorN/A—
- NCT04125472Study directorN/A—
- NCT04125472Lead sponsorN/A—
- NCT04056481Lead sponsorN/A—
- NCT05505838Study directorN/A—
- NCT05505838Lead sponsorN/A—
- NCT07223203Lead sponsorPhase 3Dec 31, 2025
- NCT07223203OfficialPhase 3Dec 31, 2025
- NCT07295717Lead sponsorPhase 1Dec 12, 2025
- NCT07295717OfficialPhase 1Dec 12, 2025
- NCT07214727Lead sponsorPhase 1Oct 15, 2025
- NCT07214727OfficialPhase 1Oct 15, 2025
- NCT07181109OfficialPhase 3Sep 22, 2025
- NCT07181109Lead sponsorPhase 3Sep 22, 2025
- NCT07052903Lead sponsorPhase 3Jul 2, 2025
Details
- Founded
- Cambridge, MA, US Jun 2, 2002
- First NDA
- Aug 10, 2018
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy